A major limitation of their use is their narrow therapeutic index and the severe myelosuppression they cause, a life threating adverse event highly associated with TPMT deficiency (Relling et al., 1999). This evidence concerns the gene TPMT and hyperinsulinemic hypoglycemia, familial, 4.